Immunotherapy Coverage From Every Angle
Advertisement
Advertisement

Recent News

KEYNOTE-010 in Advanced NSCLC: Long-Term Survival Benefit With Pembrolizumab
Phase II Durvalumab Trial in Resistant Head and Neck Cancer
Early Results of Phase I Study of CAR T-Cell Therapy in Multiple Myeloma
Novel Four-Drug Combination Therapy for Newly Diagnosed Multiple Myeloma
Clinical Trial of Personalized Vaccine in Kidney Cancer Commences
OpACIN Trial: Ipilimumab Plus Nivolumab in Stage III Melanoma
OAK Trial: Disease Progression With Atezolizumab vs Chemotherapy in NSCLC
Do PPIs Affect the Efficacy of Immunotherapy in Metastatic Melanoma?
First-Line Immunotherapy Combination in Lung Cancer
Pembrolizumab Approved for Merkel Cell Carcinoma by the FDA
ASH 2018: First-Line Combination Regimens in Transplant-Ineligible Patients With Myeloma
SABCS 2018: Adjuvant Therapies for HER2-Positive Breast Cancer Compared in KATHERINE Trial
FDA Approves Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer
Risk Class May Be Linked to Response to Breast Cancer Treatments
Is Neoadjuvant Immunotherapy Effective in Treating High-Risk Melanoma?
SABCS 2018: Duration of Adjuvant Trastuzumab in Early Breast Cancer
FDA Approves Atezolizumab Combination in First-Line Treatment of Metastatic Nonsqumous NSCLC
Pegilodecakin Plus Anti–PD-1 Therapy for Renal Cell Carcinoma
ASH 2018: Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma
Post Hoc Analysis of Pembrolizumab Versus Standard of Care in Head and Neck Cancer
Combined Immunotherapy Treatment Studied in Advanced Lung Cancer
Shorter Course of Trastuzumab in Some HER2-Positive Early Breast Cancers
Novel Approach to Forecasting Response to Cetuximab in Colorectal Cancer
Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors
Immunotherapy Combination for Metastatic Uveal Melanoma
Reduced-Dose Combination Therapy in Geriatric Patients With Metastatic Colorectal Cancer
FDA Grants Regenerative Medicine Advanced Therapy Designation to CAR T-Cell Therapy
Palliative and Supportive Care Symposium: Immunotherapy-Related Toxicities
Update on Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
City of Hope Launches CAR T-Cell Trial in Patients With Breast Cancer and Brain Metastases
ESMO 2018: Adjuvant Pembrolizumab and Quality of Life in Patients With High-Risk Melanoma
ESMO 2018: Doxorubicin vs. Gemcitabine in Bevacizumab-Based Therapy for Ovarian Cancer
Copyright © 2018 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.